Rapport Therapeutics (RAPP) Return on Capital Employed (2024 - 2026)
Rapport Therapeutics (RAPP) reported Return on Capital Employed of 25.09% for Q1 2026, up 603.0% year-over-year from 3.57% in Q1 2025, and down 1.24% quarter-over-quarter from 24.78% in Q4 2025.
Rapport Therapeutics (RAPP) Return on Capital Employed (2024 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 3 years of Return on Capital Employed data on file, last reported at 25.09% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 25.09%, up 603.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 25.09% (up 603.0% YoY), and the FY2025 annual result was 31.7%, up 498.0% from the prior year.
- Return on Capital Employed eased to 25.09% in Q1 2026 per RAPP's latest filing, from 24.78% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 22.42% in Q3 2024 and troughed at 36.1% in Q2 2025.
- A 3-year average of 27.68% and a median of 26.43% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed tumbled 538 bps in 2025, then surged 603 bps in 2026.
- A 3-year view of Return on Capital Employed shows it stood at 26.43% in 2024, then increased by 6 bps to 24.78% in 2025, then declined by 1 bps to 25.09% in 2026.
- Business Quant data shows RAPP's Return on Capital Employed at 25.09% in Q1 2026, 24.78% in Q4 2025, and 27.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Rapport Therapeutics | 1.66 Bn | 1.66 Bn | - | -25.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.09% |
| Dec 31, 2025 | -24.78% |
| Sep 30, 2025 | -27.80% |
| Jun 30, 2025 | -36.10% |
| Mar 31, 2025 | -31.12% |
| Dec 31, 2024 | -26.43% |
| Sep 30, 2024 | -22.42% |